RATIONALE: Stem cell therapies to regenerate damaged cardiac tissue represent a novel approach to treat heart disease. However, the majority of adoptively transferred stem cells delivered to damaged myocardium do not survive long enough to impart protective benefits, resulting in modest functional improvements. Strategies to improve survival and proliferation of stem cells show promise for significantly enhancing cardiac function and regeneration. OBJECTIVE: To determine whether injected cardiac progenitor cells (CPCs) genetically modified to overexpress nuclear Akt (CPCeA) increase structural and functional benefits to infarcted myocardium relative to control CPCs. METHODS AND RESULTS: CPCeA exhibit significantly increased proliferation and secretion of paracrine factors compared with CPCs. However, CPCeA exhibit impaired capacity for lineage commitment in vitro. Infarcted hearts receiving intramyocardial injection of CPCeA have increased recruitment of endogenous c-kit cells compared with CPCs, but neither population provides long-term functional and structural improvements compared with saline-injected controls. Pharmacological inhibition of Akt alleviated blockade of lineage commitment in CPCeA. CONCLUSIONS: Although overexpression of nuclear Akt promotes rapid proliferation and secretion of protective paracrine factors, the inability of CPCeA to undergo lineage commitment hinders their capacity to provide functional or structural benefits to infarcted hearts. Despite enhanced recruitment of endogenous CPCs, lack of functional improvement in CPCeA-treated hearts demonstrates CPC lineage commitment is essential to the regenerative response. Effective stem cell therapies must promote cellular survival and proliferation without inhibiting lineage commitment. Because CPCeA exhibit remarkable proliferative potential, an inducible system mediating nuclear Akt expression could be useful to augment cell therapy approaches.
RATIONALE: Stem cell therapies to regenerate damaged cardiac tissue represent a novel approach to treat heart disease. However, the majority of adoptively transferred stem cells delivered to damaged myocardium do not survive long enough to impart protective benefits, resulting in modest functional improvements. Strategies to improve survival and proliferation of stem cells show promise for significantly enhancing cardiac function and regeneration. OBJECTIVE: To determine whether injected cardiac progenitor cells (CPCs) genetically modified to overexpress nuclear Akt (CPCeA) increase structural and functional benefits to infarcted myocardium relative to control CPCs. METHODS AND RESULTS:CPCeA exhibit significantly increased proliferation and secretion of paracrine factors compared with CPCs. However, CPCeA exhibit impaired capacity for lineage commitment in vitro. Infarcted hearts receiving intramyocardial injection of CPCeA have increased recruitment of endogenous c-kit cells compared with CPCs, but neither population provides long-term functional and structural improvements compared with saline-injected controls. Pharmacological inhibition of Akt alleviated blockade of lineage commitment in CPCeA. CONCLUSIONS: Although overexpression of nuclear Akt promotes rapid proliferation and secretion of protective paracrine factors, the inability of CPCeA to undergo lineage commitment hinders their capacity to provide functional or structural benefits to infarcted hearts. Despite enhanced recruitment of endogenous CPCs, lack of functional improvement in CPCeA-treated hearts demonstrates CPC lineage commitment is essential to the regenerative response. Effective stem cell therapies must promote cellular survival and proliferation without inhibiting lineage commitment. Because CPCeA exhibit remarkable proliferative potential, an inducible system mediating nuclear Akt expression could be useful to augment cell therapy approaches.
Authors: Natalie Gude; John Muraski; Marta Rubio; Jan Kajstura; Erik Schaefer; Piero Anversa; Mark A Sussman Journal: Circ Res Date: 2006-07-13 Impact factor: 17.367
Authors: Yasuyuki Tsujita; John Muraski; Isao Shiraishi; Takahiro Kato; Jan Kajstura; Piero Anversa; Mark A Sussman Journal: Proc Natl Acad Sci U S A Date: 2006-08-01 Impact factor: 11.205
Authors: Sang Yup Lim; Yong Sook Kim; Youngkeun Ahn; Myung Ho Jeong; Moon Hwa Hong; Soo Yeon Joo; Kwang Il Nam; Jeong Gwan Cho; Peter M Kang; Jong Chun Park Journal: Cardiovasc Res Date: 2006-03-06 Impact factor: 10.787
Authors: Nicolas Noiseux; Massimiliano Gnecchi; Marco Lopez-Ilasaca; Lunan Zhang; Scott D Solomon; Arjun Deb; Victor J Dzau; Richard E Pratt Journal: Mol Ther Date: 2006-09-11 Impact factor: 11.454
Authors: Sweeta R Choudhari; Muhammad A Khan; Genesis Harris; Donald Picker; Gary S Jacob; Timothy Block; Kunwar Shailubhai Journal: Mol Cancer Ther Date: 2007-01 Impact factor: 6.261
Authors: Massimiliano Gnecchi; Huamei He; Nicolas Noiseux; Olin D Liang; Lunan Zhang; Fulvio Morello; Hui Mu; Luis G Melo; Richard E Pratt; Joanne S Ingwall; Victor J Dzau Journal: FASEB J Date: 2006-04 Impact factor: 5.191
Authors: Mark A Lampert; Amabel M Orogo; Rita H Najor; Babette C Hammerling; Leonardo J Leon; Bingyan J Wang; Taeyong Kim; Mark A Sussman; Åsa B Gustafsson Journal: Autophagy Date: 2019-02-22 Impact factor: 16.016
Authors: Mayur Vilas Jain; Jaganmohan R Jangamreddy; Jerzy Grabarek; Frank Schweizer; Thomas Klonisch; Artur Cieślar-Pobuda; Marek J Łos Journal: Cell Cycle Date: 2015-06-01 Impact factor: 4.534
Authors: Sili Zou; Pingping Ren; Lin Zhang; Alon R Azares; Sui Zhang; Joseph S Coselli; Ying H Shen; Scott A LeMaire Journal: Ann Thorac Surg Date: 2016-04-16 Impact factor: 4.330
Authors: Mirko Völkers; Haruhiro Toko; Shirin Doroudgar; Shabana Din; Pearl Quijada; Anya Y Joyo; Luis Ornelas; Eri Joyo; Donna J Thuerauf; Mathias H Konstandin; Natalie Gude; Christopher C Glembotski; Mark A Sussman Journal: Proc Natl Acad Sci U S A Date: 2013-07-10 Impact factor: 11.205